<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850534</url>
  </required_header>
  <id_info>
    <org_study_id>SILC</org_study_id>
    <nct_id>NCT04850534</nct_id>
  </id_info>
  <brief_title>Systemic Inflammation in Liver Cirrhosis</brief_title>
  <acronym>SILC</acronym>
  <official_title>Evaluation and Prognostic Indications of Systemic Inflammation in Liver Cirrhosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate systemic inflammation in liver cirrhosis patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Upper Gastrointestinal Bleeding</measure>
    <time_frame>One Year</time_frame>
    <description>Overt upper GI bleeding due to esophagogastric varices, ulcers and other causes; Identified by clinical manifestations, lab tests and endoscopy and measured by number/proportion of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>One Year</time_frame>
    <description>Deaths caused by variceal bleeding, hepatocellular carcinoma, liver failure, etc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or worsening acute decompensation event other than upper GI bleeding</measure>
    <time_frame>One Year</time_frame>
    <description>Ascites, Hepatic encephalopathy, systemic infection, spontaneous bacterial peritonitis, hepatorenal syndrome, etc Identified by clinical manifestations, lab tests and images according to renown practice guidelines and measured by number/proportion of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplantation/ Transfer to other non-endoscopic therapies</measure>
    <time_frame>One Year</time_frame>
    <description>Undergo liver transplantation, or transferred to surgical, radio-interventional, or other non-endoscopic therapies; Measured by number/proportion of patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>EGD+NSBB</arm_group_label>
    <description>Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGD</arm_group_label>
    <description>Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of liver cirrhosis with high-risk bleeding esophaogastric varices&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver cirrhosis, with endoscopy-verified high-risk esophagogastric&#xD;
             varices;&#xD;
&#xD;
          2. Adult patients aged 18-75 years;&#xD;
&#xD;
          3. Willing to anticipate and informed consent form obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of prior radio-interventional therapy (TIPS or BRTO), liver transplantation,&#xD;
             splenectomy, or hepatectomy;&#xD;
&#xD;
          2. Non-sinusoidal cirrhosis (e.g. vascular cirrhosis);&#xD;
&#xD;
          3. Coexistence with advanced hepatocellular carcinoma or other malignancies;&#xD;
&#xD;
          4. Coexistence with severe systemic diseases and less than 3 months of expected survival&#xD;
             time;&#xD;
&#xD;
          5. Acute infection within 4 weeks before recruitment;&#xD;
&#xD;
          6. Antibiotic use within 4 weeks before recruitment;&#xD;
&#xD;
          7. Initial antiviral therapy for HBV or HCV within 4 weeks before recruitment;&#xD;
&#xD;
          8. Pregnant or lactating women;&#xD;
&#xD;
          9. Patients resistant to long-term follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bin Wu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, Third Affiliated Hospital of Sun Yar-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xing Wang, M.D.</last_name>
    <phone>86-20-85252156</phone>
    <email>md04wsh@mail2.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, the Third Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhua Li, M.D.</last_name>
      <phone>86-020-85252168</phone>
      <email>IMUAWUB@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinlai Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jinlai Liu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Liver cirrhosis; Systemic inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

